Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of AJM300 in patients with active ulcerative colitis (2)
jRCT2080223867Phase 3Completed
- Sponsor
- EA Pharma Co., Ltd.
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing AJM300 with Placebo (2 arms). Started Apr 2018; status: completed.
02
Drugs
firategrast
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2080223867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223867.